314 related articles for article (PubMed ID: 18546865)
1. [Neuroendocrine differentiation and metastasized to brain stem, intraorbit and base of tongue in prostate cancer during hormonal treatment: a case report].
Sugi M; Yanishi M; Shimada O; Kawakita S; Murota T; Shikata N
Hinyokika Kiyo; 2008 May; 54(5):373-6. PubMed ID: 18546865
[TBL] [Abstract][Full Text] [Related]
2. [Neuroendocrine differentiation in adenocarcinoma of the prostate during hormonal treatment: a case report].
Matsumoto Y; Mibu H; Kagebayashi Y
Hinyokika Kiyo; 2004 Nov; 50(11):813-5. PubMed ID: 15628545
[TBL] [Abstract][Full Text] [Related]
3. [Neuroendocrine differentiation in adenocarcinoma of prostate during combined androgen blockade therapy: a case report].
Kitamoto K; Hayashi T; Tamada S; Ezaki K; Kawashima H; Sugimura K; Nakatani T
Hinyokika Kiyo; 2005 Jan; 51(1):33-5. PubMed ID: 15732339
[TBL] [Abstract][Full Text] [Related]
4. New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma.
Sciarra A; Cardi A; Dattilo C; Mariotti G; Di Monaco F; Di Silverio F
Int J Clin Pract; 2006 Apr; 60(4):462-70. PubMed ID: 16620361
[TBL] [Abstract][Full Text] [Related]
5. [A case of poorly differentiated adenocarcinoma of prostate with neuroendocrine differentiation].
Miyoshi Y; Inoue Y; Matsuzaki J; Fukuda M; Satomi Y; Akahane H; Saito S
Hinyokika Kiyo; 1998 Feb; 44(2):113-6. PubMed ID: 9546133
[TBL] [Abstract][Full Text] [Related]
6. Proptosis--an uncommon presentation of orbital metastases secondary to prostate cancer.
Vissamsetti B; McArdle PA; Adams CJ; Hotiana Z; Morton AL; Alexander RJ
Urol Int; 2007; 79(4):374-5; discussion 375. PubMed ID: 18025861
[TBL] [Abstract][Full Text] [Related]
7. [Neuroendocrine differentiation in adenocarcinoma of the prostate with progression of disease during hormonal treatment: a report of two cases].
Kosugi M; Hanawa Y; Momma T; Saito S; Hirose S
Nihon Hinyokika Gakkai Zasshi; 2003 May; 94(4):521-4. PubMed ID: 12795167
[TBL] [Abstract][Full Text] [Related]
8. A case of orbital metastasis from prostatic carcinoma as an initial symptom.
Isshiki S; Cho S; Matsuno D; Sato N; Furuya Y
Hinyokika Kiyo; 2007 Mar; 53(3):193-5. PubMed ID: 17447492
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine differentiation in the progression of prostate cancer.
Komiya A; Suzuki H; Imamoto T; Kamiya N; Nihei N; Naya Y; Ichikawa T; Fuse H
Int J Urol; 2009 Jan; 16(1):37-44. PubMed ID: 19120524
[TBL] [Abstract][Full Text] [Related]
10. [Hormone refractory prostate carcinoma metastasizes to the penis: a case report].
Kawahara T; Manabe Y; Asazuma A; Aoyama T; Hashimura T
Hinyokika Kiyo; 2009 Oct; 55(10):627-9. PubMed ID: 19938335
[TBL] [Abstract][Full Text] [Related]
11. [Impact of short-term neoadjuvant hormonal treatment on neuroendocrine differentiation in prostate carcinoma].
Li GZ; Zeng L; Zhang J; Yuan YM; Yang XY; Wang JH; Na YQ; Guo YL
Zhonghua Zhong Liu Za Zhi; 2003 Sep; 25(5):493-5. PubMed ID: 14575578
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine differentiation of localized prostate cancer during endocrine therapy.
Nemoto K; Tomita Y
Scand J Urol Nephrol; 2007; 41(6):558-60. PubMed ID: 17853028
[TBL] [Abstract][Full Text] [Related]
13. [Loss of differentiation of a prostate adenocarcinoma after hormone therapy: the example of a metastasis in the spongy body of the penis].
Uphoff J; Woziwodzki J; Schattka SO; Kollias A
Aktuelle Urol; 2008 Sep; 39(5):373-7. PubMed ID: 18798127
[TBL] [Abstract][Full Text] [Related]
14. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.
Mosca A; Berruti A; Russo L; Torta M; Dogliotti L
J Endocrinol Invest; 2005; 28(11 Suppl International):141-5. PubMed ID: 16625864
[TBL] [Abstract][Full Text] [Related]
15. [Combined small-cell carcinoma/adenocarcinoma of prostate: report of two cases].
Sakuma T; Yoshida T; Ohashi H; Nishimura K; Kawano K
Hinyokika Kiyo; 2007 Jul; 53(7):489-92. PubMed ID: 17702184
[TBL] [Abstract][Full Text] [Related]
16. [Brain metastasis of prostatic cancer: regression under hormonal treatment].
Ameur A; Touiti D; el Mostarchid B; el Alami M; Jira H; Abbar M
Prog Urol; 2001 Dec; 11(6):1298-301. PubMed ID: 11859670
[TBL] [Abstract][Full Text] [Related]
17. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
18. [Relationship of neuroendocrine differentiation to biological behavior of prostate cancer].
Wu XL; Huang KT; Chen W; Chen L; Dong L; Yu ZX
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):472-5. PubMed ID: 19567097
[TBL] [Abstract][Full Text] [Related]
19. Frequency and number of neuroendocrine tumor cells in prostate cancer: no difference between radical prostatectomy specimens from patients with and without neoadjuvant hormonal therapy.
Shimizu S; Kumagai J; Eishi Y; Uehara T; Kawakami S; Takizawa T; Koike M
Prostate; 2007 May; 67(6):645-52. PubMed ID: 17342745
[TBL] [Abstract][Full Text] [Related]
20. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells.
Yuan TC; Veeramani S; Lin MF
Endocr Relat Cancer; 2007 Sep; 14(3):531-47. PubMed ID: 17914087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]